Versuchen GOLD - Frei
Tech advancements driving growth of ePharmacy sector
Chronicle Pharmabiz
|November 27, 2025
TECHNOLOGICAL advancements have played an important role in driving the growth of India's ePharmacy industry, with companies developing several capabilities tailored specifically to the unique needs of the sector, including secure and user-friendly digital flows for prescription validation.
Additionally, supply chain technologies such as temperature-controlled logistics systems have enabled the storage, handling, and timely delivery of sensitive medications, opine experts.
India's ePharmacy industry has grown significantly, achieving an annual growth rate of around 20 per cent over the past five years. Currently valued at approximately $1.4 billion, the market still represents only around five per cent of the overall retail pharmacy sector in the form of organized ePharmacy. Key companies in this space include Tata 1mg, PharmEasy, Netmeds, Apollo 24/7, MedPlus, Flipkart Health+, and Amazon Pharmacy.
With the rising adoption of artificial intelligence, ePharmacies can unlock the potential of their vast customer data to enhance their offerings. Players will be able to drive more personalization, introducing targeted marketing and providing customized health recommendations, ultimately improving customer experience and deepening engagement, according to Prashant Tandon, CEO and co-founder of Tata 1 mg.
There are several significant trends emerging in the sector, including that companies increasingly integrating pharmacy services with diagnostics and online doctor consultations, seeking to be 'one-stop shops' for their customers' health needs. Another major trend is the adoption of omnichannel strategies, with online-first players establishing physical stores to cater to consumers preferring in-person transactions/needing immediate product access, he added.
Quick commerce is also emerging as a notable trend and its increased penetration is set to further bolster customer experience and drive wider adoption of online pharmacy services, especially for urgent medicine needs. He added that the consumers are now sticking with ePharmacies for reasons much beyond discounting – especially around convenience, comfort, availability, accessibility, etc.
Diese Geschichte stammt aus der November 27, 2025-Ausgabe von Chronicle Pharmabiz.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Chronicle Pharmabiz
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 mins
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 mins
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 mins
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 mins
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 mins
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 mins
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 mins
December 11, 2025
Listen
Translate
Change font size
